Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Canadian biotech stock investigates potential weight loss drugs

Jonathon Brown Jonathon Brown, The Market Online
0 Comments| April 17, 2024

{{labelSign}}  Favorites
{{errorMessage}}

  • FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health
  • The biotechnology company has started investigating ingredients and dietary supplements that may have the potential to promote weight loss and liver health.
  • The team is already pursuing products to promote faster alcohol metabolism and ameliorate the effects of acute alcohol intoxication
  • FSD Pharma last traded at $0.69 per share

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.

The biotechnology company has started investigating ingredients and dietary supplements that may have the potential to promote weight loss and liver health.

The team is already pursuing products to promote faster alcohol metabolism and ameliorate the effects of acute alcohol intoxication.

Certain ingredients and combinations of ingredients are being investigated that show promise in improving liver health, reducing metabolic disease, and reducing visceral fat that could lead to weight loss and liver health. The company is pursuing this pipeline to potentially create a new product line in addition to unbuzzd, a rapid alcohol detoxification drink made by Celly Nutrition Corp., a privately held company that receives investments from FSD.

Earlier this week, Celly Nutrition announced it had entered into a loan amending agreement in connection with the senior secured term loan made by FSD to increase its term loan by C$300,000 to C$1.3 million. Celly Nutrition is launching this product to assist in expediting alcohol metabolism and faster recovery from alcohol consumption.

According to Grand View Research, the global hangover cure products market size is expected to reach US$6.18 billion by 2030, representing a compound annual growth rate of 14.8 per cent from 2021 to 2028.

FSD Pharma is developing drug candidates for inflammatory diseases, drug abuse, neurodegenerative disorders and mental health disorders.

FSD Pharma Inc. (CSE:HUGE) last traded at $0.69 per share.

Join the discussion: Find out what everybody’s saying about this stock on the FSD Pharma Inc. Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.



Tags:

{{labelSign}}  Favorites
{{errorMessage}}


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company